Age Related Macular Degeneration Clinical Trial
Official title:
Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-related Macular Degeneration With Concurrent Significant Epiretinal Membrane.
Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular degeneration. Since then we have seen that is not rare to find the coexistence of these entities. An ERM may produce intrinsic disorganization of the outer retina leading to persistent increased macular thickness and/or edema. This persistent edema may affect the effectiveness in the treatment of exudative age-related macular degeneration (eAMD). Therefore, this study was designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD. ;
Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
| Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
| Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
| Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
| Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
| Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
| Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
| Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
| Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
| Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
| Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
| Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
| Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
| Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
| Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
| Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
| Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
| Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
| Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 |